We have examined interactions between the purine nucleoside analog fludarabine (9-␤-arabinofuranosyl-2-fluoroadenine) and the macrocyclic lactone bryostatin 1 in the human monocytic leukemic cell line U937. Fludarabine exerted dose-dependent effects on U937 cell viability and growth which were associated with both induction of apoptosis, as well as cellular maturation. Incubation of cells with bryostatin 1 (10 nM; 24 h) after, but not before a 6-h exposure to 10 M fludarabine resulted in a modest but significant increase in apoptosis, and was associated with greater than a 1 log reduction in clonogenicity. Subsequent exposure to bryostatin 1 also increased the percentage of fludarabine-treated cells displaying differentiation-related features (eg plastic adherence, CD11b positivity) compared to cells exposed to fludarabine alone. Bryostatin 1 did not increase the retention of the active fludarabine metabolite, Fara-ATP, nor did it increase 3 H-F-ara-A incorporation into DNA. Despite its capacity to trigger cellular maturation, fludarabine exposure (either with or without bryostatin 1) failed to induce the cyclin-dependent kinase inhibitors (CDKIs) p21 WAFI/CIP1 and p27
Introduction
The purine analog fludarabine phosphate (9-␤-arabinofuranosyl-2-fluoroadenine monophosphate; FAMP) is a deoxyadenosine analog which is a potent inhibitor of leukemic cell growth. 1 FAMP is rapidly converted to the primary metabolite, 9-␤-arabinofuranosyl-2-fluoroadenine (F-ara-A) by ubiquitous phosphatases present in serum and plasma, and is subsequently phosphorylated intracellularly to form the active derivative, 9-␤-arabinofuranosyl-2-fluoroadenine triphosphate (F-ara-ATP). The cytotoxic actions of F-ara-ATP may stem from multiple actions, including inhibition of DNA polymerase ␣ and DNA primase, inhibition of ribonucleotide reductase, and nucleoside incorporation into DNA and/or RNA. [2] [3] [4] In lymphoid cells, fludarabine induces apoptosis, an event that appears to be critically dependent upon DNA incorporation. 5 bine has shown significant activity in lymphoid malignancies such as chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin's lymphoma, but has also been used in the treatment of acute myelogenous leukemia (AML), either as a single agent, 6 or in combination with 1-␤-d-arabinofuranosylcytosine (ara-C). 7 Bryostatin 1 is a macrocyclic lactone activator of protein kinase C (PKC), and is currently undergoing phase I and II evaluation. 8 Bryostatin 1 variably induces maturation in human leukemic cell lines and primary AML blast specimens, 9, 10 although it is considerably weaker in this regard than the tumor-promoting phorbol diester, 12-phorbol-13-myristate acetate (PMA). 11, 12 The basis for the divergent spectrum of activity of bryostatin 1 and phorbols remains unknown, but may involve differential PKC isoform activation or translocation. 13, 14 Notably, bryostatin 1 is a potent down-regulator of PKC, a process recently linked to proteasomal degradation of the enzyme. 15 Previous studies from this laboratory have demonstrated that bryostatin 1 increases the susceptibility of human leukemia cells (eg HL-60; U937) to apoptosis induced by ara-C in a dose-and sequence-dependent manner. 16, 17 In a human promyelocytic leukemic line (HL-60) insensitive to the differentiation-inducing actions of bryostatin 1, pretreatment with bryostatin 1 augmented ara-C-mediated apoptosis. 17 In contrast, in the human monocytic leukemic cell line U937, exposure of ara-C-pretreated cells to bryostatin 1 significantly increased apoptosis, whereas exposure to bryostatin 1 before ara-C did not. 18 Currently, it is unknown whether the ability of bryostatin 1 to promote ara-C-induced apoptosis in human leukemia cells is restricted to this pyrimidine antimetabolite, or can be extended to include other nucleoside analogs. The purpose of this study was to characterize the antiproliferative effects of the purine analog fludarabine in human myelomonocytic U937 leukemia cells in relation to induction of apoptosis and differentiation, and to determine what effect, if any, bryostatin 1 might have on these actions.
Materials and methods

Cells
U937 cells were derived from a patient with diffuse histiocytic leukemia as previously described. 12 The cells were maintained in RPMI 1640 (GIBCO, Grand Island, NY, USA) supplemented with 10% fetal calf serum (FCS), MEM vitamins, sodium pyruvate, and penicillin and streptomycin (all GIBCO). Flasks were kept in a 37°C, 5% CO 2 , fully humidified incubator and cells were passaged twice weekly.
Transfectant U937 cells stably overexpressing the antiapoptotic protein Bcl-2 were generated by electroporation of the parental line with a plasmid (pCEP4; Invitrogen, Carlsbad, CA, USA) containing Bcl-2 cDNA under the control of an 1047 CMV promotor and a hygromycin resistance marker as previously described. 19 These cells, designated U937/Bcl-2, express approximately a seven-fold increase in Bcl-2 protein compared to their empty-vector counterparts (U937/pCEP4) and are maintained in 400 g/ml hygromycin (GIBCO) for selection pressure. Levels of other Bcl-2 family members, including Bcl-x L and Bax, have been found to be equivalent in the two lines.
We have previously described a HL-60 cell line stably expressing the cyclin-dependent kinase inhibitor (CDKI) p21 WAFI/CIPI in the antisense configuration. 20 More recently, we have characterized the behavior of a U937 cell line that also exhibits p21 WAFI/CIPI dysregulation. 21 In response to the tumorpromoting phorbol PMA, antisense-expressing cells (U937/ASF4) are impaired in G 1 arrest, cellular maturation, pRB dephosphorylation, and CDK2 inhibition compared to empty vector controls (U937/pREP4). These cells are maintained under selection pressure in medium containing 200 g/ml hygromycin.
Drugs and chemicals
Bryostatin 1 was provided by Dr Anthony Murgo, Cancer Treatment and Evaluation Program/Division of Cancer Treatment, National Cancer Institute (Bethesda, MD, USA). It was stored under light-protected conditions as a lyophilized powder at 4°C, and reconstituted in sterile dimethylsulfoxide (DMSO) prior to use. Material was subsequently diluted in RPMI medium to achieve the desired final concentration; in all cases, the final concentration of DMSO was Ͻ0.1%, and found to exert negligible effects on the U937 cell responses. Fludarabine was provided by Dr Gary Williams, Berlex Laboratories (Richmond, CA, USA), stored under light-protected conditions at room temperature, and formulated in sterile water prior to use. H-fludarabine (10 Ci/mmol) was purchased from Moravek Biochemicals (Brea, CA, USA). F-ara-ATP was kindly provided by Dr W Plunkett, MD Anderson Cancer Center (Houston, TX, USA). Deoxyadenosine triphosphate (dATP) was purchased from Sigma (St Louis, MO, USA).
Experimental format
Logarithmically growing cells (approximately 4 × 10 5 cells/ml) were placed in 25 cm 2 T-flasks (Costar, Cambridge, MA, USA) and incubated in the presence of fludarabine (generally 10 m) for 6 h. At the end of this period, cells were washed three times in drug and serum-free medium, and resuspended in fresh medium containing 10% FCS at 2 × 10 5 cells/ml in the presence or absence of bryostatin 1 (10 nm) for an additional 24 h. In some cases, cells were exposed to these agents in the opposite sequence, eg bryostatin 1 → fludarabine. At the end of the incubation period, cells were harvested and prepared for analysis as described below.
Assays of apoptosis
Following appropriate drug exposures, cell morphology and apoptosis was measured by cytocentrifuge preparations stained with the Diff-Quik stain set (Dade Diagnostics, Aguada, PR, USA), as previously described. 12 The percentage of cells exhibiting classic apoptotic features (eg cell shrinkage, nuclear condensation, the formation of membrane-bound blebs, etc) was determined by examining 7-10 randomly selected fields and scoring at least 1000 cells/condition. In some cases, results were confirmed by monitoring DNA fragmentation following treatment of cell lysates with bisbenzamide staining as described previously. 17 
Differentiation studies
Two separate methods were employed to monitor induction of leukemic cell maturation. First, after the designated incubation period (eg 24-72 h), the number of cells in suspension was determined using a hematocytometer. Subsequently, adherent cells were removed using a cell scraper, additional medium added, and the cell number assessed as above. The percentage of adherent cells, characteristic of a differentiated phenotype, was expressed relative to the total population (eg adherent cells + cells in suspension).
Alternatively, cellular maturation was assessed by monitoring expression of the myelomonocytic surface marker CD11b by flow cytometry, as described previously. 12 Briefly, treated cells were pelleted at 500 g and resuspended in cold phosphate-buffered saline (PBS) at 5 ×10 6 cells/ml. The cell suspension was mixed with fluorescein isothiocyanate-labeled antibody (CD11b or IgG2␣, Becton Dickinson, Mountain View, CA, USA) and placed on ice for 20 min. Cells were diluted in cold PBS and analyzed using a Becton Dickinson FACScan flow cytometer and Verity Winlist software. In some studies CD11b expression was measured separately in the adherent and suspension cell populations.
Clonogenic assays
A previously described method was employed. 17 Briefly, after drug treatment, cells were washed three times in drug-free medium, cell numbers normalized, and 500 cells/well plated in 12-well plates containing RPMI medium, 20% FCS, and 0.3% Bacto agar (Difco, Detroit, MI, USA). The plates were placed in a 37°C, 5% CO 2 , fully-humidified incubator for 12 days, after which colonies, consisting of groups of у50 cells, were scored using an Olympus Model CK inverted microscope (Olympus, Lake Success, NY, USA).
Western analysis
Whole cell pellets (5 × 10 6 cells/condition) were washed once in PBS, resuspended in 100 l PBS, and lysed by the addition of 100 l 2X loading buffer (1× = 30 mm Tris-base, pH 6.8, 2% SDS, 2.88 mm ␤-mercaptoethanol, 10% glycerol, ෂ0.01% bromophenol blue). Lysates were sonicated, boiled for 10 min, centrifuged at 12 800 g for 5 min, and quantified using Coomassie protein assay reagent (Pierce, Rockford, IL, USA). Equal amounts of protein (25 g) were separated by SDS-PAGE (5% stacker and 12% resolving gels) and electroblotted to Optitran nitrocellulose filters (Schleicher and Schleicher, Keene, NH, USA). The membrane was stained in 0.1% amido black and destained in 5% acetic acid to ensure transfer and equal loading. The blots were then blocked in PBSTween (PBS-T; 0.05%)/5% dry milk for 1 h at 22°C, and probed overnight at 4°C with primary antibody: p21 
F-ara-ATP retention
After treatment, 20 × 10 6 cells/condition were washed in cold PBS, lysed in 0.6 n TCA, and extracted in 1:3.5 Trioctylamine:1,1,2-Trichlorotrifluoroethane (Sigma-Aldrich). The aqueous phase was stored at −80°C until analysis. Immediately prior to column addition, the samples were thawed and extracted in succession with 0.5 m sodium periodate, 4 m methylamine, and 1 m rhamnose to convert the NTPs to their respective bases. 22 Extracts were run on a Waters radial-pak 10 u SAX cartridge (Waters, Millipore, Bedford, MA, USA), monitored at 254 nm on a Beckman 160 detector (Beckman, Fullerton, CA, USA), and analyzed with a BioRad Model 700 Chromatography Workstation (Version 3.63 software; Biorad, Hercules, CA, USA). Samples were run at 3 ml/min for 22 min in 25% ammonium phosphate (0.75 m, pH 3.7)/75% ammonium phosphate (5 mm, pH 2.8), then ramped up to 100% of the 0.75 m ammonium phosphate over the next 40 min. Peaks were identified by relative retention time compared to authentic F-ara ATP and deoxyadenine triphosphate. 
H-F-ara-A DNA incorporation
Cells were incubated with 10 m 3 H-fludarabine (final specific activity = 8.6 Ci/mmol) for 6 h, washed free of drug, and incubated in either drug-free medium or medium containing 10 nm bryostatin 1 for an additional 24 h. Alternatively, cells were incubated with 10 nm bryostatin 1 for 24 h prior to a 6-h exposure to 3 H-fludarabine. At the end of the incubation period, the cells were lysed and the DNA extracted as previously described. 2 Radioactivity was quantified by scintillography, and the amount of 
Statistical analysis
The significance of the difference between experimental conditions was determined utilizing the Student's t-test for unpaired observations. To assess the interaction between agents, Median Dose Analysis was employed 23 using a commercially available software program (CalcuSyn; Biosoft, Ferguson, MO, USA). For these studies, the combination index (CI) was calculated for a two-drug combination involving a fixed concentration ratio. Using these methods, CI values Ͻ1.0 indicate a synergistic interaction.
Results
The sequence-dependent effects of sequential exposure of cells to fludarabine and bryostatin 1 on apoptosis in U937 cells are shown in Figure 1a . Following treatment of cells with 10 m fludarabine for 6 h and a subsequent 24 h incubation in drug-free medium, a relatively small number of cells displayed apoptotic features (eg ෂl8%). Treatment of cells with bryostatin 1 alone for 24 h also weakly induced apoptosis in these cells. When cells were exposed to the sequence fludarabine → bryostatin 1, the percentage of apoptotic cells approached 30%. When cells were exposed to bryostatin 1 before fludarabine, the extent of apoptosis also increased, albeit additively, but was less than that observed for the sequence fludarabine → bryostatin 1 (P р 0.05). In each case, parallel effects on DNA fragmentation were observed (data not shown).
Reductions in clonogenicity following exposure of cells to fludarabine or bryostatin 1 administered individually or sequentially are illustrated in Figure 1 b. In each case, inhibition of colony formation was considerably greater than the extent of apoptosis observed at the end of the drug incubation interval (Figure 1a) . When cells were exposed to the sequence fludarabine → bryostatin 1, the reduction in colony formation was Ͼ1 log. The sequence bryostatin 1 → fludarabine also led to a significant reduction in colony formation (eg Ͼ80%), although inhibitory effects were not as great as those observed for the opposite sequence (P р 0.05). Median dose effect analysis employing varying concentrations of fludarabine (0.2-20 m) and bryostatin 1 (0.2-20 nm) at a fixed ratio (1000:1) in the sequence fludarabine → bryostatin 1 resulted in combination index values Ͻ1, indicating a synergistic interaction (Figure 1c) .
To determine whether enhancement of fludarabine-related apoptosis by bryostatin 1 might stem from altered drug metabolism, retention of the active fludarabine metabolite F-ara-ATP was monitored over time in fludarabine-treated cells subsequently incubated in drug-free or bryostatin 1-containing medium ( Figure 2 ). It can be seen that degradation of the triphosphate derivative was relatively rapid with either treatment, in that levels became virtually undetectable by 12 h of incubation. Furthermore, exposure of cells to bryostatin 1 did not result in a discernable difference in the rate of F-ara-ATP degradation (Figure 2a) . Ratios of F-ara-ATP to its physiologic counterpart, dATP at 2 h and 6 h after a 6-h incubation with fludarabine were also unaltered by bryostatin 1 treatment (Figure 2b) . Finally, incorporation of 3 H-fludarabine into U937 cell DNA was not significantly altered by either a 24-h preincubation with or subsequent exposure to 10 nm bryostatin 1 (Figure 2c ). Thus, enhanced fludarabine metabolism could not be invoked to explain the modulatory effects of bryostatin 1 on fludarabine actions.
Because of the discordance between the extent of apoptosis induced by exposure to fludarabine/bryostatin 1 and the correspondingly greater reduction in cellular proliferative potential, an attempt was made to determine whether additional mechanisms (eg cellular maturation) might be involved in this phenomenon. Fludarabine dose-response curves for induction of U937 cell differentiation, reflected by the extent of cellular adherence or CD11b expression, are shown in Figure 3a . In the case of the latter, separate determinations were conducted in the adherent and suspension cell populations. With both assays, a biphasic dose-response was observed, with maximal differentiation induction occurring at fludarabine concentrations of 0.5 to 1.0 m, and declining at higher levels. For comparison, a fludarabine-induced apoptosis dose-response curve is shown in Figure 3b , demonstrating an increase in cell death at fludarabine concentrations greater or equal to those associated with maximal maturation responses (eg 1.0 m). A discordance was noted between fludarabine-stimulated adherence and CD11 b positivity, in that the percentage of adherent cells displayed increases over basal levels at drug concentration of 0.01-1.0 m, whereas increased CD11b expression occurred primarily at fludarabine concentrations of 0.5-2.0 m. Unexpectedly, the extent of CD11b positivity was equivalent in the adherent and suspension cell populations, further indicating that these two maturation markers (cellular adherence and CD11b expression) are not induced in parallel in fludarabine-treated cells. Lastly, the effects of the combi- (Figure 3c ). When cells were exposed to the sequence fludarabine → bryostatin (a) Logarithmically growing cells were exposed to the designated concentration of F-ara-A for 72 h after which the percentage of cells displaying plastic adherence (), adherent cells expressing CD11b (̄) or cells in suspension expressing CD11b (̆) was determined as described in Materials and methods. Open symbols correspond to cells incubated in drug-free medium. (b) Alternatively, the percentage of cells exhibiting apoptotic features following a 72-h incubation with various concentrations of F-ara-A was determined as described above. *Indicates significantly greater than control values; P р 0.05; ** = P р 0.01. (c) Cells were exposed to either drug-free medium (C) or 10 10 nm bryostatin 1 (B) for 72 h, or to 10 m Fara-A for 6 h followed by a 72-h incubation in medium (F) or 10 nm bryostatin 1 (F → B). The percentage of CD1 1b + cells was determined by flow cytometry. In each case, values represent the means for three separate experiments ± s.d.
1 (F-ara-A; 10 m; 6 h, washed, BRY: 10 nm; 72 h), the percentage of cells expressing CD11b increased to 26.3 ±6.3%. However, combination with bryostatin 1 did not lead to a further potentiation of maturation in cells exposed to lower concentrations of fludarabine (eg 0.5-1.0 m; data not shown). These results suggest that sequential exposure of U937 cells to fludarabine and bryostatin 1 can lead to an increased maturation response, although this effect is only apparent at higher concentrations of fludarabine (10 m). In parallel studies, utilizing the 10 m concentration of fludarabine, the percentage of apoptotic cells at the 72-h interval was 8.9 ± 0.9% vs 14.2 ± 3.8% for fludarabine and the fludarabine → bryostatin 1 sequence, respectively (data not shown), consistent with results of previous studies demonstrating the late appearance of apoptosis in leukemic cells undergoing differentiation. 24 The effects of a 72 h exposure to a lower concentration of fludarabine (1.0 m) on induction of apoptosis and inhibition of cloning efficiency were then separately examined in the suspension and adherent cell populations (Figure 4) . Contrary to expectations, the reduction in cloning efficiency (relative to controls) following fludarabine treatment was equivalent in both groups (eg ෂ10%). However, the percentage of apoptotic cells was significantly greater in the suspension fraction (P Ͻ 0.0001). Similar results were observed following treatment with a lower dose of fludarabine (0.3 m) (data not shown). These findings suggest that the loss of self-renewal in fludarabine-treated cells displaying certain differentiation-related features (eg plastic adherence) is equivalent to that which results from enhanced apoptosis (eg in the suspension cell fraction).
Induction of leukemic cell maturation (eg by the tumor-promoting phorbol PMA) is associated with increased expression of the cyclin-dependent kinase inhibitor p21 CIP1/WAF1 . 20 To determine whether a similar mechanism is operative in U937 cells undergoing differentiation in response to bryostatin 1 and fludarabine, Western blot analysis was employed ( Figure 5a ). As we have recently reported, 12 10 nm bryostatin 1 failed to induce p21 CIP1/WAF1 at any point during the 72-h exposure interval. Furthermore, neither fludarabine alone, nor the combination of fludarabine and bryostatin 1 led to increased p21 CIP1/WAF1 expression over this time period. In contrast, exposure of cells to 10 nm PMA resulted in clear induction of p21 CIP1/WAF1 at 24 h, which increased modestly over the ensuing 48 h. In separate studies, the combination of fludarabine and bryostatin 1 was not associated with increased expression of the CDK1 p27 KIP1 (data not shown). These findings suggest that differentiation induction by fludarabine (± bryostatin 1) can proceed in the absence of p21 CIP1/WAF1 induction. To Cells were exposed to 10 m F-ara-A for 6 h, washed, and incubated in either fresh medium (F-ara-A) or medium containing 10 nm bryostatin 1 (F-ara-A→BRY) for an additional 72 h. Control, incubation in drug-free media; and BRY, cell treated with 10 nm bryostatin 1. (a) Aliquots of the cell suspension were lysed at 24-h intervals, proteins (10 g/condition) separated by PAGE gel electrophoresis, and probed with anti-p21 monoclonal antibody as described in the text. As a control, protein extracted from cells exposed to 10 nm PMA for 24-72 h was also subjected to Western blot analysis. The results of a representative study are shown; two additional experiments yielded equivalent findings. might nevertheless be involved in the apoptotic response to fludarabine, a U937 cell line stably expressing p21 CIP1/WAF1 in the antisense configuration was employed (U937/p21ASF4). Following exposure to PMA, these cells display diminished p21 CIP1/WAF1 induction, G 1 arrest, pRb dephosphorylation, CDK2 inhibition, and acquisition of differentiation-related features compared to their empty vector counterparts (pREP4), 21 in a manner analogous to that previously described in p21 antisense-expressing HL60 cells. 20 Despite the fact that fludarabine failed to induce p21 CIP1/WAF1 , cells exhibiting p21 CIP1/WAF1 dysregulation were significantly more sensitive to fludarabine-induced apoptosis compared to controls (Figure 5b; left panel) . Conversely, dysregulation of p21 CIP1/WAF1 significantly reduced the susceptibility of U937 to fludarabine-mediated differentiation induction (Figure 5b; right panel) .
The effects of Bcl-2 overexpression on the apoptotic response of cells to fludarabine were then examined ( Figure  6 ). When cells were exposed to varying concentrations of fludarabine for 6 h followed by a 24-h incubation in drug-free medium, a significantly smaller percentage of Bcl-2-overexpressing cells (U937/Bcl-2) exhibited apoptotic features compared to their counterparts transfected with an empty vector (U937/pCEP4) (Figure 6a ). When Bcl-2-overexpressing cells were sequentially exposed to fludarabine followed by bryostatin 1, the extent of apoptosis, while less than that observed in the pCEP4 line, was greater than that noted in control cells treated with fludarabine alone (Figure 6b ). These results are compatible with recent findings indicating that bryostatin 1 reverses, at least in part, resistance to ara-C-related apoptosis conferred by Bcl-2 overexpression in the HL-60 promyelocytic leukemia cell line. 19 Lastly, effects on cellular maturation were compared in cells containing an empty vector and those overexpressing Bcl-2 ( Figure 7) . When fludarabine was administered alone, differentiation induction in Bcl-2 overexpressors was either equal to or, in most cases, greater than, that observed in their empty vector-containing counterparts ( Figure  7a) . Furthermore, when U937/Bcl-2 cells were sequentially exposed to fludarabine followed by bryostatin 1, the increase in CD11b positivity was at least as great or greater than that noted in the case of untransfected or empty vector controls (Figure 7b ). These findings indicate that Bcl-2 overexpression does not protect cells from the maturation-related actions of fludarabine (or the fludarabine/bryostatin 1 combination), but may under some circumstances increase the susceptibility of cells to differentiation induction.
Discussion
The results described herein demonstrate that fludarabine induces both apoptosis and differentiation in U937 cells, and that each of these events is enhanced, at least to a degree, by the macrocyclic lactone bryostatin 1. Furthermore, sequential (a) Empty-vector control cells (U937/pCEP4) () and Bcl-2-overexpressing cells (U937/Bcl-2) () were exposed to the designated concentration of fludarabine for 6 h, washed, and incubated in drug-free medium for 24 h prior to determination of the extent of apoptosis. * = Values significantly less than those obtained for U937/pCEP4; P р0.05. (b) Alternatively, U937/pCEP4 (solid bars) and U937/Bcl-2 (open bars) cells were exposed to drug-free medium (C), 10 nm bryostatin 1 for 24 h (B), or the sequence 10 m F-ara-A for 6 h → ± 10 nm bryostatin 1 for 24 h (F, F → B) which the percentage of apoptotic cells was determined. * = Greater than values obtained for U937/Bcl-2 cells; P р 0.05. In all cases, values represent the means for three to four separate experiments performed in triplicate ± s.d. administration of fludarabine followed by bryostatin 1 leads to a marked reduction in colony formation, which exceeds the extent to which cells display the classic morphologic features of apoptosis (and DNA fragmentation) at both early (24 h) and late (72 h) intervals. Previous studies have described a discordance between induction of apoptosis by agents such as aphidicolin and VP-16 and inhibition of colony formation, 25, 26 the basis for which may be multifactorial. For example, formation of colonies consisting of у50 cells requires at least six cell divisions; consequently, an intervention that slows DNA synthesis could reduce the number of colonies in the absence of an increase in cell death. Alternatively, non-apoptotic cell death programs, including giant cell formation 26 or mitotic forms of cell death 27 could contribute to inhibition of clonogenicity. In this context, it has been postulated that early events associated with commitment to cell death and loss of self-renewal capacity exist, and that these can be dissociated from the classic signs of apoptotic morphology and accompanying biochemical features (eg caspase activation). 28 By analogy, induction of leukemic cell dif- ferentiation can by itself limit leukemic cell self-renewal capacity, although the appearance of apoptosis in differentiating cells, generally as a late, presumably secondary event, is well documented. 24 Lastly, a disproportionate susceptibility of clonogenic cells to apoptosis could also account for the observed discordance.
The observation that administration of bryostatin 1 after, but not before, exposure of cells to fludarabine resulted in an increase in apoptosis is consistent with previous studies demonstrating the sequence-dependent potentiation of leukemic cell death following treatment with DNA-damaging and differentiation-inducing agents. 29, 30 It is also compatible with the finding that subsequent (but not prior) exposure to bryostatin 1 augments apoptosis in U937 cells treated with the pyrimidine analog ara-C. 17 It is noteworthy that U937 cells are considerably more susceptible to apoptosis induced by ara-C (± bryostatin 1) than fludarabine, inasmuch as the extent of cell death induced by 1 m ara-C exceeds that produced by a 10-fold higher concentration of fludarabine (unpublished observ-ations). This phenomenon might reflect reduced conversion of fludarabine to its lethal triphosphate derivative in U937 cells, or alternatively, the relatively limited retention of F-ara-ATP following removal of drug in this cell line (Figure 2) . In either case, subsequent treatment with bryostatin 1 failed to increase F-ara-ATP retention or incorporation of 3 H-fludarabine into leukemic cell DNA, rendering it unlikely that these events account for the enhanced apoptosis observed with this drug combination.
It appears likely that at least a component of the antiproliferative actions of fludarabine in U937 cells stems from its capacity to induce cellular maturation. Previous studies have shown that low concentrations of pyrimidine (eg ara-C) or purine (eg 6-thioguanine) analogs induce differentiation in leukemic cell lines, a phenomenon that may be related to antimetabolite-mediated inhibition of DNA synthesis. 31, 32 To the best of our knowledge, induction of leukemic cell maturation by fludarabine has not previously been described. While apoptosis accompanies induction of leukemic cell differentiation (eg by retinoic acid), generally as a relatively late event, 24 a reciprocal relationship has been noted between early events associated with leukemic cell differentiation and apoptosis. 33 In this regard, the modest capacity of fludarabine to induce apoptosis in these cells may be counterbalanced by an enhanced ability to trigger cellular maturation. Moreover, while bryostatin 1 has been reported to induce U937 cell maturation, 34 we 12 and others 35 have found it to be considerably more limited in this capacity than tumor-promoting phorbols such as PMA. Nevertheless, sequential exposure of cells to fludarabine followed by bryostatin 1 did lead to a net increase in cellular differentiation, an event that very likely contributed to the antiproliferative effects of this drug combination. Since cellular maturation, like cell death, leads to a loss of leukemic cell self-renewal capacity, such a phenomenon could help explain the observed discordance between the increased but still relatively modest induction of apoptosis by fludarabine and bryostatin 1 and the more substantial reduction in clonogenic survival. In this context, it is worth noting that after exposure to lower concentrations of fludarabine (eg 0.3 or 1.0 m), the reduction in cloning efficiency was comparable in the adherent and suspension cell fractions, despite enhanced apoptosis in the latter (Figure 4 ). It has previously been shown that following maturation induction (eg by PMA), leukemic cells initially become adherent, and after they undergo apoptosis, detach from the sides of the flask. 36 Thus, induction of leukemic cell death and differentiation may both contribute, in a reciprocal manner, to the loss of clonogenic survival.
The CDKI p21 CIP1/WAF1 has been implicated in G 1 arrest accompanying leukemic cell differentiation induced by PMA. 37, 38 In contrast, results from this laboratory 20 and others 37 indicate that DNA damage induced by antimetabolites such as ara-C does not trigger a p21 response, at least in p53-null human leukemia cells such as HL-60. 39 Similarly, exposure of U937 cells to fludarabine failed to induce p21 CIP1/WAF1 , despite the ability of this agent to induce cellular maturation. We have also reported that bryostatin 1 is impaired in its capacity to induce p21 CIP1/WAF1 in U937 cells when administered at low concentrations (eg 10 nm). 12 Despite its association with enhanced differentiation, the combination of bryostatin 1 and fludarabine also failed to induce p21 CIP1/WAF1 expression (Figure 5a ), implicating alternative pathways in the maturation response to these agents. Nevertheless, the observation that p21 dysregulation (ie in p21 antisense-expressing cells; Figure 5b ) attenuated fludarabinemediated differentiation suggests that this CDK1 contributes in some yet-to-be determined way to drug-induced maturation. The latter finding is consistent with the recent observation that dysregulation of p21 CIP1/WAF1 significantly reduces the differentiation response of U937 cells to PMA, 21 raising the possibility that phorbol-and drug-induced maturation proceed, at least to a certain extent, along a common pathway. It is important to note that dysregulation of p21 CIP1/WAF1 did increase the susceptibility of U937 cells to fludarabinemediated apoptosis. Recent studies have shown that interference with p21 CIP1/WAF1 -mediated G 1 arrest in p53+ colon tumor cells potentiates apoptosis triggered by DNA-damaging agents, presumably by interfering with DNA repair mechanisms and/or by uncoupling S-phase and mitosis. 40, 41 A similar phenomenon may be operative in p53-null U937 leukemic cells exposed to fludarabine.
Overexpression of Bcl-2 protects cells from the lethal actions of diverse chemotherapeutic agents, 42 and the observation that U937/Bcl-2 cells were less susceptible to fludarabine-induced apoptosis than their empty vector-containing counterparts (Figure 6a ) is consistent with these findings. Similarly, the partial restoration of fludarabine-mediated apoptosis by bryostatin 1 is similar to that which we have recently reported in the case of Bcl-2-overexpressing HL-60 cells exposed to ara-C, 19 indicating that this phenomenon is not restricted to pyrimidine analogs. Furthermore, overexpression of Bcl-2 clearly did not antagonize maturation resulting from combined exposure of cells to fludarabine and bryostatin 1. In this regard, previous studies have demonstrated that enforced expression of Bcl-2 in HL-60 cells does not impair differentiation induction (eg by retinoic acid), although it does delay the onset of apoptosis. 43, 44 In the present studies, induction of differentiation by fludarabine (± bryostatin 1) was as least as great, (and in some cases, greater) in Bcl-2-overexpressing cells than in controls. This phenomenon might best be understood in the context of evidence demonstrating that apoptosis and differentiation represent alternative and, under some circumstances, mutually exclusive cellular fates. 33 For example, U937 cells exhibiting dysregulation of PKC␦ undergo apoptosis rather than maturation in response to phorbol esters. 45 More recently, differentiation or apoptosis induced by interferon-␥ in human neuroblastoma cells have been shown to represent mutually exclusive processes at the single cell level. 46 Thus, dysregulation of early maturation events may sensitize cells to apoptosis; conversely, initiation of apoptosis and the accompanying cellular disruption may prevent cells from engaging a normal differentiation program. In light of these possibilities, it is tempting to speculate that Bcl-2-mediated protection against fludarabine-mediated apoptosis renders cells more susceptible to the maturation-promoting actions of this agent.
In summary, the results of the present studies demonstrate that fludarabine induces both apoptosis and differentiation in U937 cells, and that the latter process proceeds in the absence of detectable p21 CIP1/WAF1 induction. Moreover, fludarabinemediated apoptosis and maturation are each enhanced by subsequent exposure of cells to bryostatin 1, and it appears likely that both processes contribute to the antiproliferative effects of this drug sequence. Lastly, bryostatin 1-mediated potentiation of fludarabine-induced cell death and differentiation also occurs in cells displaying enforced expression of Bcl-2. In view of the recent introduction of bryostatin 1 into clinical trials in humans, 8 and preclinical evidence that it may enhance the cytotoxicity of established nucleoside analogs such as ara-C, 16 chlorodeoxyadenosine, 47 and fludarabine (this study), further investigation of these drug combinations appears warranted.
